Incidence and adverse clinical events of primary sclerosing cholangitis with ulcerative colitis

• Published in: International journal of colorectal disease 2023-06, Vol.38 (1), p.175-175, Article 175
• Main Authors: Han, In Sub, Baek, Dong Hoon, Hong, Seung Min, Lee, Bong Eun, Lee, Moon Won, Kim, Gwang Ha, Song, Geun Am
• Format: Article
• Language: English
• Subjects: Gastroenterology; Hepatology; Internal Medicine; Medicine; Medicine & Public Health; Proctology; Surgery
• ISSN: 1432-1262; 1432-1262
• DOI: 10.1007/s00384-023-04464-z

Purpose The aim of this study was to conduct a nationwide population-based study to estimate the incidence of primary sclerosing cholangitis in patients with ulcerative colitis (UC-PSC) and investigate healthcare use, medication use, surgery, cancer, and death as adverse clinical events of UC-PSC. Methods We identified incident cases of UC with (UC-PSC) or without PSC (UC-alone) between 2008 and 2018 using health insurance claims data in Korea. Univariate (crude hazard ratio (HR)) and multivariate analyses were performed to compare the risk of adverse clinical events between groups. Results A total of 14,406 patients with UC using population-based claims data were detected in the cohort. Overall, 3.38% (487/14,406) of patients developed UC-PSC. During a mean follow-up duration of approximately 5.92 years, the incidence of PSC in patients with UC was 185 per 100,000 person-years. The UC-PSC group showed statistically more frequent healthcare use (hospitalization and emergency department visits: HRs, 5.986 and 9.302, respectively; P